Current Role of Immunotherapy in Multiple Myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F98%3A00000038" target="_blank" >RIV/65269705:_____/98:00000038 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Current Role of Immunotherapy in Multiple Myeloma

Popis výsledku v původním jazyce

Myeloablative chemotherapy improved the results of multiple myeloma treatment but the disease remains incurable. Residual disease eradication is one of the main clues for further improvement of the prognosis of myeloma patients. New methods-consolidationtherapy, antibodies, gene therapy, interleukins, immunotoxines, dendritic cells, vaccines and induction of graft-versus-tumor effect, are tested in the phase I/II clinical trials. Adoptive cellular immunotherapy anf progress in inductions of graft versus myeloma effect are very promising. We are still not able to transfer very good preclinical result of immunotherapy into clinical result in vivo measured by event free and long-term survivals. Combination of myeloablative therapy followed a new type ofimmunotherapy focussing on residual disease eradication evaluated in the setting of sensitive disease may be optimal. Such approach could improve the current

Název v anglickém jazyce

Current Role of Immunotherapy in Multiple Myeloma

Popis výsledku anglicky

Myeloablative chemotherapy improved the results of multiple myeloma treatment but the disease remains incurable. Residual disease eradication is one of the main clues for further improvement of the prognosis of myeloma patients. New methods-consolidationtherapy, antibodies, gene therapy, interleukins, immunotoxines, dendritic cells, vaccines and induction of graft-versus-tumor effect, are tested in the phase I/II clinical trials. Adoptive cellular immunotherapy anf progress in inductions of graft versus myeloma effect are very promising. We are still not able to transfer very good preclinical result of immunotherapy into clinical result in vivo measured by event free and long-term survivals. Combination of myeloablative therapy followed a new type ofimmunotherapy focussing on residual disease eradication evaluated in the setting of sensitive disease may be optimal. Such approach could improve the current

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/IZ4253" target="_blank" >IZ4253: Aktivace autologního transplantátu hematopoetických kmenových buněk interleukinem 2.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

1998

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Medica Austriaca

ISSN

0303-8173

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—